Engineered kidneys: principle, progress and prospects

Jamie Davies, C-Hong Chang, Melanie Lawrence, Christopher G. Mills, John Mullins

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

There is an urgent need for new ways to treat end-stage renal disease, by promoting regeneration in situ, by repopulating decellularized donor organs with a patient's own stem cells, or by making entirely new kidneys. There are two broad strategies for making new kidneys: precision engineering by positioning everything exactly - for example by 3D printing – or supporting cells' self-organizing ability. We describe the latter approach, which begins with a suspension of renogenic stem cells and produces a small kidney with nephrons, a collecting duct system, active transport and an ability to integrate with host vasculature. Many problems have to be solved before these kidneys are directly clinically useful, including size, maturation, provision of a ureter, and production from human iPS cells. Even the existing engineered kidneys, if they can be made from human rather than animal cells, may be useful for assays for adverse drug reactions that will be free of the problems of extrapolating from animal tests to predicted human responses.
Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalAdvances in Regenerative Biology
Volume1
Issue number1
DOIs
Publication statusPublished - 25 Sep 2014

Fingerprint Dive into the research topics of 'Engineered kidneys: principle, progress and prospects'. Together they form a unique fingerprint.

Cite this